Trials 20
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 117 trials | ||||||
| Phase 1 | NCT06910839 | Mar → May 2025 | obesity disorder | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT06541678 | Dec 2024 → Mar 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06567327 | Aug 2024 → Mar 2025 | obesity disorder | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06568731 | Aug → Dec 2024 | obesity disorder | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06153758 | Nov 2023 → Sep 2024 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05093205 | Oct 2021 → Jul 2022 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04889157 | Jul 2021 → Feb 2022 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04839393 | Apr → Oct 2021 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04616027 | Jan 2021 → Feb 2022 | impaired renal function disease, type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04604496 | Dec 2020 → Jan 2022 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04621227 | Dec 2020 → May 2021 | obesity disorder | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04616339 | Nov 2020 → Jul 2021 | obesity disorder | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04552470 | Oct 2020 → Mar 2021 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04495140 | Jul → Oct 2020 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03538743 | Jun 2018 → May 2019 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03492697 | Apr → Jul 2018 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03309241 | Oct 2017 → Feb 2018 | — | Pfizer | Completed | No outcome recorded |
| Phase 23 trials · 2 met primary | ||||||
| Phase 2 | NCT04707313 | Jan 2021 → Sep 2023 | obesity disorder | Pfizer | Completed | Met primary |
| Phase 2 | NCT04617275 | Jan → Nov 2021 | obesity disorder, type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT03985293 | Oct 2019 → Jun 2021 | type 2 diabetes mellitus | Pfizer | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-07-11 | Pfizer | Results Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron pfizer.com ↗
To date, study results have demonstrated a pharmacokinetic profile supportive of once-daily dosing. |
| 2023-12-01 | Pfizer | Results Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity pfizer.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-04-14 | Pfizer | Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron pfizer.com ↗ |
| 2024-07-11 | Pfizer | Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron pfizer.com ↗ |
| 2023-12-01 | Pfizer | Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity pfizer.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Danuglipron | “This randomized, double-blind, placebo-controlled Phase 2b study aimed to assess the efficacy, safety, and tolerability of danuglipron (PF-06882961), an oral small-molecule...” PMID 40539310 ↗ Jun 20257“We developed danuglipron (PF-06882961), an oral small-molecule GLP-1R agonist and found it had comparable efficacy to injectable peptidic GLP-1R agonists in a humanized mouse model.” PMID 34127852 ↗ Jun 2021 “Danuglipron (PF-06882961) is an oral, small-molecule glucagon-like peptide-1 receptor agonist in development for the treatment of type 2 diabetes (T2D) and obesity.” PMID 37840155 ↗ Nov 2023 “subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation A” NCT04616339 ↗ |
| Known as | PF-06882961 | “This randomized, double-blind, placebo-controlled Phase 2b study aimed to assess the efficacy, safety, and tolerability of danuglipron (PF-06882961), an oral small-molecule...” PMID 40539310 ↗ Jun 202515“We developed danuglipron (PF-06882961), an oral small-molecule GLP-1R agonist and found it had comparable efficacy to injectable peptidic GLP-1R agonists in a humanized mouse model.” PMID 34127852 ↗ Jun 2021 “Danuglipron (PF-06882961) is an oral, small-molecule glucagon-like peptide-1 receptor agonist in development for the treatment of type 2 diabetes (T2D) and obesity.” PMID 37840155 ↗ Nov 2023 |
| Action | Activate | “Glucagon-like peptide 1 receptor agonist” CHEMBL4518483 ↗1“GLP-1R agonist” PMID 34127852 ↗ Jun 2021 |
| Modality | Small molecule | “an oral small-molecule GLP-1R agonist” PMID 34127852 ↗ Jun 2021 |
| Route | Oral | “single oral doses of PF-06882961” NCT03309241 ↗ |
| Target | GLP1R | “Glucagon-like peptide 1 receptor agonist” CHEMBL4518483 ↗ |